Transcript Systems Engineering Research and the Cancer Care

Systems Engineering Research and the Cancer
Care Engineering Project
Joseph F. Pekny, Ph. D. (Purdue University)
Professor of Chemical Engineering
Interim Head of Industrial Engineering
Cancer Care Engineering
Project Leads:
Pat Loehrer, MD
Kenneth Wiseman Professor of Medicine
Director, IU Simon Cancer Center
Associate Dean of Cancer Research
Indiana University School of Medicine
Joe Pekny, PhD
Professor of Chemical Engineering
Interim Department Chair, Industrial Engineering
Founder, Regenstrief Center for Healthcare Engineering
Purdue University
Marietta Harrison, PhD
Professor of Medicinal Chemistry
Associate Vice President for Research
Director, Oncological Sciences Center
Purdue University
Notre Dame Joins CCE
Project Funding
• U.S. Army Medical and Materiel
Command
– $2.3M
– Negotiating additional award
• Regenstrief Foundation
– $1.35M
• Walther Cancer Foundation
– $1.8M
• NIH (2) and DoD (1) pending
Opportunity: Further Systematizing
Cancer Care Innovation
Thousands of Journal
Articles, Best Practices,
Landmark Studies,
Rapid IT Advances,
Large Amounts of Data,
Systems Biology, Golden
Age of Life Science
Breakthrough Cures,
Uneven Care, “Miracle”
Patients, Policy Needs,
Ongoing Opportunity for
Reality to Research and
Back
Cancer Care Engineering
Science & Technology
Cancer Care Practice
“We want to know with certainty whether the treatment
protocol for a young, non-smoking mother of 3 with colon
cancer will work. Today we can only tell her in terms of
percentages the potential treatment effectiveness. The
monthly cost is in the tens of thousands and may not be
effective for her. We order it and hope.”
Goal
• Needs Better Tool Now
• Needs Way to Rapidly Improve Tools
Going Forward by Applying More,
Advancing, and Targeting Science and
Technology
CCE Summary: Processing Samples, in Position to Develop First Generation Pilot Tools
CCE Component in Progress
Prevention & Treatment: Sample
Acquisition & Analysis (Colorectal
Cancer): Patient Subgroups
Personalizing Cancer Care: The
Importance of Patient Groups
Clinical Trials
Phase
I
Phase
II
Clinical Trials
Phase
III
Phase
I
Phase
II
Phase
III
On which patient groups does Drug X work?
Patient groups are indistinguishable with respect to
treatment
Clinical Trials
Phase
What
I
Clinical TrialsDrug
Phase
I
Phase
II
Phase isPhase
dosage
best?
II
III
X
Phase
III
Clinical Trials
Phase
I
Phase
II
Phase
III